- Home
- COCH vs PASG Comparison
COCH vs PASG Comparison
Compare COCH & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COCH | PASG |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 29.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | COCH | PASG |
|---|---|---|
| Price | $0.81 | $9.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $9.50 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 448.5K | 44.2K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $29.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $5.12 |
| 52 Week High | $2.25 | $20.20 |
Technical Indicators
Market Signals| Indicator | COCH | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 50.34 | 58.34 |
| Support Level | $0.80 | $8.23 |
| Resistance Level | $0.86 | $10.71 |
| Average True Range (ATR) | 0.05 | 0.89 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 59.29 | 70.67 |
Price Performance
Historical ComparisonAbout COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.